Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-05-14 18:30 |
Kommuniké från årsstämman i Xbrane Biopharma
|
Swedish | 71.4 KB | ||
| 2020-05-13 08:00 | Swedish | 442.9 KB | |||
| 2020-05-13 08:00 | English | 442.0 KB | |||
| 2020-05-06 08:02 |
Xbrane och STADA ingår partnerskap med Bausch + Lomb för kommersialisering av X…
|
Swedish | 80.6 KB | ||
| 2020-05-06 08:00 |
Xbrane and STADA partner with Bausch + Lomb for commercialization of Xlucane in…
|
English | 80.2 KB | ||
| 2020-04-16 08:00 | Swedish | 2.0 MB | |||
| 2020-04-16 08:00 | English | 1.9 MB | |||
| 2020-04-15 08:00 |
Notice of annual general meeting in Xbrane Biopharma AB
|
English | 130.1 KB | ||
| 2020-04-15 08:00 |
Kallelse till årsstämma i Xbrane Biopharma AB
|
Swedish | 135.2 KB | ||
| 2020-04-02 08:30 |
Xlucane är fortfarande på väg mot regulatoriskt godkännande innan Lucentis® för…
|
Swedish | 71.0 KB | ||
| 2020-04-02 08:30 |
Xlucane is still on track towards regulatory approval ahead of Lucentis® patent…
|
English | 70.8 KB | ||
| 2020-02-28 08:00 | Swedish | 747.1 KB | |||
| 2020-02-28 08:00 | English | 749.9 KB | |||
| 2020-02-21 16:15 |
Maris Hartmanis declines re-election for 2020
|
English | 64.1 KB | ||
| 2020-02-21 16:15 |
Maris Hartmanis ställer inte upp för omval 2020
|
Swedish | 64.8 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
